.png)
Technologies that can harness the power of RNA-targeted therapeutics have the potential to transform the way we treat diseases, resulting in new blueprints for future medicines.
We have a novel discovery platform to identify new RNA drugs on a scale and throughput that is currently inaccessible to the state-of-the-art.
CEO
CSO
Advisor
CTO
CFO
VP of RNA Biology
COO
Hiring Manager
Massachusetts Founders Network shares how InFocus Therapeutics, co-founded by Emily Fang and Kyle Giesler, is transforming RNA drug discovery.
InFocus Therapeutics was featured on BFM Business, where CEO Emily Fang discussed the company’s groundbreaking work in RNA-targeted drug discovery.
Emily Fang introduces us to InFocus, a company working on small molecule RNA modulation, and shares her thoughts on the local biotech ecosystem.
InFocus was selected amongst over 1,300 startups into the prestigious Berkeley SkyDeck Pad-13 Program. Our CSO will represent the company to join the three-months program starting in May 2024. As a Pad-13 member, the InFocus team receives exclusive access to world-class resources from the SkyDeck Program as well as the faculty and alumni network of UC Berkeley.
Our efforts to develop innovative RNA-targeting small molecule therapeutics for patients in oncology will be greatly accelerated by PSCC’s top experts in the academic-to-industry continuum, with comprehensive network and infrastructure to data, technologies, laboratories and funding support.
InFocus is proud to be accepted into the selective Founder Institute's Silicon Valley Flagship Program, the world's leading pre-seed startup accelerator.
info@domain.com
